Last reviewed · How we verify
cyclosporin + mycophenolate mofetil
cyclosporin + mycophenolate mofetil is a immunosuppressant Small molecule drug developed by Centre Hospitalier Universitaire, Amiens. It is currently in Phase 3 development for Prevention of organ rejection in kidney transplant patients, Prevention of organ rejection in liver transplant patients.
Cyclosporin is an immunosuppressant that inhibits calcineurin, while mycophenolate mofetil is an inhibitor of inosine monophosphate dehydrogenase, both of which are involved in the activation of T cells.
Cyclosporin is an immunosuppressant that inhibits calcineurin, while mycophenolate mofetil is an inhibitor of inosine monophosphate dehydrogenase, both of which are involved in the activation of T cells. Used for Prevention of organ rejection in kidney transplant patients, Prevention of organ rejection in liver transplant patients.
At a glance
| Generic name | cyclosporin + mycophenolate mofetil |
|---|---|
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Drug class | immunosuppressant |
| Target | calcineurin, inosine monophosphate dehydrogenase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Cyclosporin works by binding to cyclophilin, which then inhibits calcineurin. This inhibition prevents the activation of T cells by blocking the transcription of IL-2. Mycophenolate mofetil, on the other hand, inhibits inosine monophosphate dehydrogenase, an enzyme involved in the synthesis of guanosine nucleotides, which are necessary for T cell activation. By inhibiting these enzymes, both drugs reduce the immune response and prevent transplant rejection.
Approved indications
- Prevention of organ rejection in kidney transplant patients
- Prevention of organ rejection in liver transplant patients
Common side effects
- Nausea
- Diarrhea
- Hypertension
- Anemia
- Leukopenia
Key clinical trials
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (PHASE2)
- Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia (PHASE2)
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cyclosporin + mycophenolate mofetil CI brief — competitive landscape report
- cyclosporin + mycophenolate mofetil updates RSS · CI watch RSS
- Centre Hospitalier Universitaire, Amiens portfolio CI
Frequently asked questions about cyclosporin + mycophenolate mofetil
What is cyclosporin + mycophenolate mofetil?
How does cyclosporin + mycophenolate mofetil work?
What is cyclosporin + mycophenolate mofetil used for?
Who makes cyclosporin + mycophenolate mofetil?
What drug class is cyclosporin + mycophenolate mofetil in?
What development phase is cyclosporin + mycophenolate mofetil in?
What are the side effects of cyclosporin + mycophenolate mofetil?
What does cyclosporin + mycophenolate mofetil target?
Related
- Drug class: All immunosuppressant drugs
- Target: All drugs targeting calcineurin, inosine monophosphate dehydrogenase
- Manufacturer: Centre Hospitalier Universitaire, Amiens — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of organ rejection in kidney transplant patients
- Indication: Drugs for Prevention of organ rejection in liver transplant patients
- Compare: cyclosporin + mycophenolate mofetil vs similar drugs
- Pricing: cyclosporin + mycophenolate mofetil cost, discount & access